Author(s):
Risna Agustina, Ronny Lesmana, Neily Zakiyah, Siti Nuriyatus Zahrah, Ajeng Diantini, Helmi
Email(s):
helmi@farmasi.unmul.ac.id , ajeng.diantini@unpad.ac.id , nuriyatuszahra@gmail.com
DOI:
10.52711/0974-360X.2024.00074 
Address:
Risna Agustina1,2, Ronny Lesmana3,4, Neily Zakiyah1,4, Siti Nuriyatus Zahrah5, Ajeng Diantini1*, Helmi6
1Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran,
West Java, Indonesia.
2Department Clinical Pharmacy, Faculty of Pharmacy, Mulawarman University, Samarinda,
East Borneo, Indonesia.
3Physiology Division, Department of Biomedical Sciences, Faculty of Medicine, Universitas Padjadjaran, West Java, Indonesia.
4Center of Excellence in Higher Education for Pharmaceutical Care Innovation,
Universitas Padjadjaran, West Java, Indonesia.
5Department of Public Health Science, Faculty of Public Health, Airlangga University, East Java, Indonesia.
6Department Pharmacology and Toxicology, Faculty of Pharmacy, Mulawarman University,
Samarinda, East Borneo, Indonesia.
*Corresponding Author
Published In:
Volume - 17,
Issue - 2,
Year - 2024
ABSTRACT:
Various internal and external factors negatively affect the homeostatic balance of the individual at the whole-body level and cause a state of stress. Stress affects the state of comfort and causes changes in energy consumption mechanisms to combat its effects. Individuals may be immunocompromised, susceptible to pathogens. Stress biomarkers play an important role in the prognosis of stress-related diseases and disorders, and therapy. In addition, different components have been identified as potent mediators of cardiovascular, central nervous system, hepatic, and nephrological disorders, which can also be used to evaluate these conditions precisely, but with strict validation and specificity. Considerable scientific progress has been made in the quantization and application of these biomarkers. This review describes current advances in biomarker identification, their prognostic and therapeutic value. Articles review were carried out using the scooping review method by identifying research publications that match the theme through an online search system. The result of this review is that 31 stress-related biomarkers have an important role in the prognosis of stress-related diseases and disorders, and have been identified as potent mediators of cardiovascular, central nervous system, hepatic, and nephrological disorders. From this review, it can be concluded that chronic stress can cause pathological responses in the body due to disruption of body homeostasis in the long term, resulting in changes in the value of physiological biomarkers of the body. The specific biomarkers that are affected then can be used as diagnostic or prognostic biomarkers.
Cite this article:
Risna Agustina, Ronny Lesmana, Neily Zakiyah, Siti Nuriyatus Zahrah, Ajeng Diantini, Helmi. The Utilization of Biomarkers in Stress-Related Diseases. Research Journal of Pharmacy and Technology. 2024; 17(2):471-8. doi: 10.52711/0974-360X.2024.00074
Cite(Electronic):
Risna Agustina, Ronny Lesmana, Neily Zakiyah, Siti Nuriyatus Zahrah, Ajeng Diantini, Helmi. The Utilization of Biomarkers in Stress-Related Diseases. Research Journal of Pharmacy and Technology. 2024; 17(2):471-8. doi: 10.52711/0974-360X.2024.00074 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2024-17-2-2
REFERENCES:
1. Billman G. E. Homeostasis: The Underappreciated and Far Too Often Ignored Central Organizing Principle of Physiology. Frontiers in Physiology. 2020; 11: 200. https://doi.org/10.3389/fphys.2020.00200
2. Chrousos G. P. Stress and disorders of the stress system. Nature reviews. Endocrinology. 2009; 5(7): 374–381. https://doi.org/10.1038/nrendo.2009.106
3. Chrousos, G. P., & Gold, P. W. The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis. JAMA,. 1992; 267(9): 1244–1252.
4. Griffiths H. R., Moller L. Biomarkers. Mol Aspects Med. 2002; 23: 101–208. 10.1016/S0098-2997(02)00017-1
5. Dadar M., Dhama K., Iqbal H., Munjal A., Khandia R., Karthik K., et al. Molecular signatures of biomarkers in cancer development, diagnosis, and its prognostic accuracy. Curr. Biomarkers. 2016; 6: 89–96. 10.2174/2468422807666170210164253
6. Prajapati B. M., Gupta J. P., Pandey D. P., Parmar G. A., Chaudhari J. D. Molecular markers for resistance against infectious diseases of economic importance. Vet. World. 2017; 10: 112–120. 10.14202/vetworld.2017.112-120
7. McEwen B. S. Biomarkers for assessing population and individual health and disease related to stress and adaptation. Metabolism. 2015; 64: S2–S10. 10.1016/j.metabol.2014.10.029
8. Marco-Ramell A., de Almeida A. M., Cristobal S., Rodrigues P., Roncada P., Bassols A. Proteomics and the search for welfare and stress biomarkers in animal production in the one-health context. Mol. Biosyst. 2016; 12: 2024–2035. 10.1039/c5mb00788g
9. Naylor S. Biomarkers: current perspectives and future prospects. Expert Rev. Mol. Diagn. 2003; 3: 525–529. 10.1586/14737159.3.5.525
10. Jain K. K. 2010. The Handbook of Biomarkers. New York, NY: Springer, 1–457
11. Sahu P., Pinkalwar N., Dubey R. D., Paroha S., Chatterjee S., Chatterjee T. Biomarkers: an emerging tool for diagnosis of a disease and drug development. Asian J. Res. Pharm. Sci. 2011;1: 9–16
12. Drucker, Elisabeth & Krapfenbauer, Kurt. Pitfalls and Limitations in Translation from Biomarker Discovery to Clinical Utility in Predictive and Personalised Medicine. 2014; 10.1201/b17137-11.
13. Maltais-Payette I., Boulet M. M., Prehn C., Adamski J., Tchernof A. 2018. Circulating glutamate concentration as a biomarker of visceral obesity and associated metabolic alterations. Nutr. Met. 2018; 15: 78. 10.1186/s12986-018-0316-5
14. Deftos L. J. Chromogranin A: its role in endocrine function and as an endocrine and neuroendocrine tumor marker. Endocr. Rev. 1991; 12: 181–187. 10.1210/edrv-12-2-181
15. Bílek R., Vlček P., Šafarík L., Michalský D., Novák K., Dušková J., et al. Chromogranin A in the laboratory diagnosis of Pheochromocytoma and Paraganglioma. Cancers (Basel). 2019; 11:E586. 10.3390/cancers11040586
16. Wu L. L., Chiou C. C., Chang P. Y., Wu J. T. Urinary 8-OHdG: a marker of oxidative stress to DNA and a risk factor for cancer, atherosclerosis and diabetics. Clin. Chim. Acta. 2004; 339: 1–9. 10.1016/j.cccn.2003.09.010
17. Franken C., Koppen G., Lambrechts N., Govarts E., Bruckers L., Den Hond E., et al. Environmental exposure to human carcinogens in teenagers and the association with DNA damage. Environ. Res. 2017; 152: 165–174. 10.1016/j.envres.2016.10.012
18. Ferguson M. A., Vaidya V. S., Waikar S. S., Collings F. B., Sunderland K. E., Gioules C. J., et al. Urinary liver-type fatty acid-binding protein predicts adverse outcomes in acute kidney injury. Kidney Int. 2010; 77: 708–714. 10.1038/ki.2009.422
19. Kamijo-Ikemori A., Kimura K. Urinary liver-type fatty acid binding protein and chronic kidney disease. Indian J Nephrol. 2015; 25: 263–264. 10.1007/s11010-005-9047-9
20. Zhou H., Cheruvanky A., Hu X., Matsumoto T., Hiramatsu N., Cho M. E., et al. Urinary exosomal transcription factors, a new class of biomarkers for renal disease. Kidney Int. 2008; 74: 613–621. 10.1038/ki.2008.206
21. Zhou H., Kajiyama H., Tsuji T., Hu X., Leelahavanichkul A., Vento S., et al. Urinary exosomal Wilms' tumor-1 as a potential biomarker for podocyte injury. Am. J. Physiol. Renal Physiol. 2013; 305: F553–F559. 10.1152/ajprenal.00056.2013
22. Skálová S. The diagnostic role of urinary N-acetyl-beta-D-glucosaminidase (NAG) activity in the detection of renal tubular impairment. Acta Med. 2005; 48: 75–80.
23. Han W. K., Waikar S. S., Johnson A., Betensky R. A., Dent C. L., Devarajan P., et al. Urinary biomarkers in the early diagnosis of acute kidney injury. Kidney Int. 2008; 73: 863–869. 10.1038/sj.ki.5002715
24. Jungbauer C. G., Birner C., Jung B., Buchner S., Lubnow M., von Bary C., et al. 2011. Kidney injury molecule-1 and N-acetyl-ß-d-glucosaminidase in chronic heart failure: possible biomarkers of cardiorenal syndrome. Eur. J. Heart Failure. 2011; 13: 1104–1110. 10.1093/eurjhf/hfr102
25. Papouin T., Haydon P. G. D-serine measurements in brain slices or other tissue explants. Bio. Protoc. 2018; 8:e2698. 10.21769/BioProtoc.2698
26. MacKay M. B., Kravtsenyuk M., Thomas R., Mitchell N. D., Dursun S. M., Baker G. B. D-serine: potential therapeutic agent and/or biomarker in schizophrenia and depression? Front. Psychiatry. 2019; 10:25 10.3389/fpsyt.2019.00025
27. Arai Y., Takeuchi H., Oishi K., Yoshida O. Osteocalcin: is it a useful marker of bone metastasis and response to treatment in advanced prostate cancer? Prostate. 1992; 20: 169–177. 10.1002/pros.2990200302
28. Mishra A. Saliva biomarkers: the unsung hero of diagnostics. J. Mol. Genet. Med. 2017; 11:288 10.4172/1747-0862.1000288
29. Anderson S. T., Kidd L. J., Barton A. J., Greer R. M. Serum bone biomarkers osteocalcin and pyridinoline in mares during pregnancy and lactation, and in foals during early post-natal life. Res. Vet. Sci. 2018; 118: 34–40. 10.1016/j.rvsc.2018.01.007
30. Fukuda M. E., Iwadate Y., Machida T., Hiwasa T., Nimura Y., Nagai Y., et al. Cathepsin D is a potential serum marker for poor prognosis in glioma patients. Cancer Res. 2005; 65: 5190–5194. 10.1158/0008-5472.CAN-04-4134
31. Mishra A. Saliva biomarkers: the unsung hero of diagnostics. J. Mol. Genet. Med. 2017;11:288 10.4172/1747-0862.1000288
32. Mishra A. Saliva biomarkers: the unsung hero of diagnostics. J. Mol. Genet. Med. 2017; 11:288 10.4172/1747-0862.1000288
33. Graham D. Y., Miftahussurur M. Helicobacter pylori urease for diagnosis of Helicobacter pylori infection: a mini review. J. Adv. Res. 2018; 13: 51–57. 10.1016/j.jare.2018.01.006
34. Delafoy L., Gelot A., Ardid D., Eschalier A., Bertrand C., Doherty A. M., et al. Interactive involvement of brain derived neurotrophic factor, nerve growth factor, and calcitonin gene related peptide in colonic hypersensitivity in the rat. Gut. 2006; 55: 940–945. 10.1136/gut.2005.064063
35. Mishra A. 2017. Saliva biomarkers: the unsung hero of diagnostics. J. Mol. Genet. Med. 2017; 11:288 10.4172/1747-0862.1000288
36. Jasim H., Carlsson A., Hedenberg-Magnusson B., Ghafouri B., Ernberg M. Saliva as a medium to detect and measure biomarkers related to pain. Sci. Rep. 2018; 8:3220. 10.1038/s41598-018-21131-4
37. Zhu Z. W., Friess H., Wang L., Zimmermann A., Büchler M. W. 2001. Brain-derived neurotrophic factor (BDNF) is upregulated and associated with pain in chronic pancreatitis. Dig. Dis. Sci. 2001; 46: 1633–1639. 10.1023/A:101068491
38. Gehlken C., Suthahar N., Meijers W. C., de Boer R. A. Galectin-3 in heart failure: an update of the last 3 years. Heart Fail Clin. 2018; 14: 75–92. 10.1016/j.hfc.2017.08.009
39. Sciacchitano S., Lavra L., Morgante A., Ulivieri A., Magi F., De Francesco G. P., et al. Galectin-3: one molecule for an alphabet of diseases, from A to Z. Int. J. Mol. Sci. 2018; 19: E379. 10.3390/ijms19020379
40. Kufe D. W. Mucins in cancer: function, prognosis and therapy. Nat. Rev. Cancer. 2009; 9: 874–885. 10.1038/nrc2761
41. Chen J., Tellez G., Richards J. D., Escobar J. Identification of potential biomarkers for gut barrier failure in broiler chickens. Front. Vet. Sci. 2015; 2:14. 10.3389/fvets.2015.00014
42. Celi P., Verlhac V., Pérez Calvo E., Schmeisser J., Kluenter A. M. Biomarkers of gastrointestinal functionality in animal nutrition and health. Anim. Feed Sci. Tech. 2018; 250: 9–31. 10.1016/j.anifeedsci.2018.07.012
43. Bademler S., Zirtiloglu A., Sari M., Ucuncu M. Z., Dogru E. B., Karabulut S. Clinical significance of serum membrane-bound mucin-2 levels in breast cancer. Biomolecules. 2019; 9:E40. 10.3390/biom9020040
44. Siddiqui I., Majid H., Abid S. Update on clinical and research application of fecal biomarkers for gastrointestinal diseases. World J. Gastroint. Pharmacol. Ther. 2017; 8: 39–46. 10.4292/wjgpt.v8.i1.39
45. Mayeur S., Spahis S., Pouliot Y., Levy E. Lactoferrin, a pleiotropic protein in health and disease. Antioxid. Redox Signal. 2016; 24: 813–836. 10.1089/ars.2015.6458
46. Siddiqui I., Majid H., Abid S. Update on clinical and research application of fecal biomarkers for gastrointestinal diseases. World J. Gastroint. Pharmacol. Ther. 2017; 8: 39–46. 10.4292/wjgpt.v8.i1.39
47. Bandara I. A., Baltatzis M., Sanyal S., Siriwardena A. K. Evaluation of tumor M2-pyruvate kinase (Tumor M2-PK) as a biomarker for pancreatic cancer. World J. Surg. Oncol. 2018;16:56. 10.1186/s12957-018-1360-3
48. Mahata S. K., Kiranmayi M., Mahapatra N. R. Catestatin: a master regulator of cardiovascular functions. Curr. Med. Chem. 2018; 25: 1352–1374. 10.2174/0929867324666170425100416
49. Ohman L., Stridsberg M., Isaksson S., Jerlstad P., Simrén M. Altered levels of fecal chromogranins and secretogranins in IBS: relevance for pathophysiology and symptoms? Am. J. Gastroenterol. 2012; 107: 440–447. 10.1038/ajg.2011.458
50. Magnusson M. K., Lasson A., Stridsberg M., Isaksson S., Strid H., Öhman L. Faecal secretogranin and chromogranin levels persist over time and are unrelated to disease history and outcome in patients with ulcerative colitis. Cogent. Med. 2018; 5:1484602 10.1080/2331205X.2018.1484602
51. Onopiuk A., Tokarzewicz A., Gorodkiewicz E. Cystatin C: a kidney function biomarker. Adv. Clin. Chem. 2015; 68: 57–69. 10.1016/bs.acc.2014.11.007
52. Ogawa-Akiyama A., Sugiyama H., Kitagawa M., Tanaka K., Onishi A., Yamanari T., et al. Serum cystatin C is an independent biomarker associated with the renal resistive index in patients with chronic kidney disease. PLoS ONE. 2018; 13:e0193695. 10.1371/journal.pone.0193695
53. Takahashi S., Nakasatomi M., Takei Y., Ikeuchi H., Sakairi T., Kaneko Y., et al. Identification of urinary activin A as a novel biomarker reflecting the severity of acute kidney injury. Sci. Rep. 2018; 8:5176. 10.1038/s41598-018-23564-3
54. Hammarsten O., Mair J., Möckel M., Lindahl B., Jaffe A. S. Possible mechanisms behind cardiac troponin elevations. Biomarkers. 2018; 23: 725–734. 10.1080/1354750X.2018.1490969
55. Adeghate E. Visfatin: structure, function and relation to diabetes mellitus and other dysfunctions. Curr. Med. Chem. 2008; 15: 1851–1862. 10.2174/092986708785133004
56. Baldassarre M. P. A., Andersen A., Consoli A., Knop F. K., Vilsbøll T. Cardiovascular biomarkers in clinical studies of type 2 diabetes. Diabetes Obes. Metab. 2018; 20: 1350–1360. 10.1111/dom.13247
57. Cymbaluk-Płoska A., Chudecka-Głaz A., Pius-Sadowska E., Sompolska-Rzechuła A., Machalinski B., Menkiszak J. Circulating serum level of visfatin in patients with endometrial cancer. BioMed. Res. Int. 2018: 8576179. 10.1155/2018/8576179
58. Baker N. L., Hunt K. J., Stevens D. R., Jarai G., Rosen G. D., Klein R. L., et al. Association between inflammatory markers and progression to kidney dysfunction: examining different assessment windows in patients with type 1 diabetes. Diabetes Care. 2018; 41: 128–135. 10.2337/dc17-0867
59. Vainer N., Dehlendorff C., Johansen J. S. Systematic literature review of IL-6 as a biomarker or treatment target in patients with gastric, bile duct, pancreatic and colorectal cancer. Oncotarget. 2018; 9: 29820–29841. 10.18632/oncotarget.25661
60. Baldassarre M. P. A., Andersen A., Consoli A., Knop F. K., Vilsbøll T. Cardiovascular biomarkers in clinical studies of type 2 diabetes. Diabetes Obes. Metab. 2018; 20: 1350–1360. 10.1111/dom.13247
61. Shrotriya S., Walsh D., Nowacki A. S., Lorton C., Aktas A., Hullihen B., et al. Serum C-reactive protein is an important and powerful prognostic biomarker in most adult solid tumors. PLoS ONE. 2018; 13: e0202555. 10.1371/journal.pone.0202555
62. Tamm N. N., Seferian K. R., Semenov A. G., Mukharyamova K. S., Koshkina E. V., Krasnoselsky M. I., et al. Novel immunoassay for quantification of brain natriuretic peptide and its precursor in human blood. Clin. Chem. 2008; 54: 1511–1518. 10.1373/clinchem.100545
63. Pandit K., Mukhopadhyay P., Ghosh S., Chowdhury S. Natriuretic peptides: diagnostic and therapeutic use. Indian J. Endocrinol. Metab. 2011; 15: S345–S353. 10.4103/2230-8210.86978
64. Vodovar N., Mebazaa A., Januzzi J. L., Jr., Murtagh G., Stough W. G., Adams K. F., Jr., et al. Evolution of natriuretic peptide biomarkers in heart failure: implications for clinical care and clinical trials. Int. J. Cardiol. 2018; 254: 215–221. 10.1016/j.ijcard.2017.11.001
65. Polineni S., Parker D. M., Alam S. S., Thiessen-Philbrook H., McArthur E., DiScipio A. W., et al. Predictive ability of novel cardiac biomarkers ST2, Galectin-3, and NT-ProBNP before cardiac surgery. J. Am. Heart Assoc. 2018; 7:e008371. 10.1161/JAHA.117.008371
66. Stanciu A. E., Stanciu M. M., Vatasescu R. G. NT-proBNP and CA 125 levels are associated with increased pro-inflammatory cytokines in coronary sinus serum of patients with chronic heart failure. Cytokine. 2018; 1: 13–19. 10.1016/j.cyto.2018.07.037
67. Tessier-Vetzel D., Tissier R., Chetboul V., Carlos C., Nicolle A., Benbaron D., et al. Diagnostic and prognostic value of endothelin-1 plasma concentrations in dogs with heart and respiratory disorders. Vet. Rec. 2006; 158: 783–788. 10.1136/vr.158.23.783
68. Odler B., Foris V., Gungl A., Müller V., Hassoun P. M., Kwapiszewska G., et al. Biomarkers for pulmonary vascular remodeling in systemic sclerosis: a pathophysiological approach. Front. Physiol. 2018; 9: 587. 10.3389/fphys.2018.00587
69. Yu D., Cai Y., Zhou W., Sheng J., Xu Z. The potential of angiogenin as a serum biomarker for diseases: systematic review and meta-analysis. Dis. Markers. 2018:1984718. 10.1155/2018/1984718
70. Hettinga Y. M., Scheerlinck L. M., Lilien M. R., Rothova A., de Boer J. H. The value of measuring urinary β2-microglobulin and serum creatinine for detecting tubulointerstitial nephritis and uveitis syndrome in young patients with uveitis. JAMA Ophthalmol. 2015; 133: 140–145. 10.1001/jamaophthalmol.2014.4301
71. Lu H. Y., Ning X. Y., Chen Y. Q., Han S. J., Chi P., Zhu S. N., et al. Predictive value of serum creatinine, blood urea nitrogen, uric acid, and β2-microglobulin in the evaluation of acute kidney injury after orthotopic liver transplantation. Chinese Med. J. 2018; 131: 1059–1066. 10.4103/0366-6999.230726
72. Ye X., Liu Y., Li F. Biomarkers of oxidative stress in the assessment of enantioselective toxicity of chiral pesticides. Curr. Protein Pept. Sci. 2017; 18: 33–40. 10.2174/1389203717666160413124654
73. Colombo G., Reggiani F., Cucchiari D., Portinaro N. M., Giustarini D., Rossi R., et al. Plasma protein-bound di-tyrosines as biomarkers of oxidative stress in end stage renal disease patients on maintenance hemodialysis. BBA Clin. 2017; 7: 55–63. 10.1016/j.bbacli.2016.12.004
74. Soto-Mendez M. J., Aguilera C. M., Mesa M. D., Campaña-Martín L., Martín-Laguna V., Solomons N. W., et al. Strong associations exist among oxidative stress and antioxidant biomarkers in the circulating, cellular and urinary anatomical compartments in Guatemalan children from the western highlands. PLoS ONE. 2016; 11: e0146921 10.1371/journal.pone.0146921
75. García-Blanco A., Baquero M., Vento M., Gil E., Bataller L., Chafer-Pericas C. Potential oxidative stress biomarkers of mild cognitive impairment due to Alzheimer disease. J. Neurol. Sci. 2017; 373: 295–302. 10.1016/j.jns.2017.01.020
76. Segerstrom SC, Miller GE. Psychological stress and the human immune system: A meta-analytic study of 30 years of inquiry. Psychol Bull. 2004; 130: 601–30.
77. Greenberg JS. Comprehensive stress management. 7th ed. New York: McGraw-Hill; 2002.
78. Liu LY, Coe CL, Swenson CA, Kelly EA, Kita H, Busse WW. School examination enhances airway examination to antigen challenge. Am J Resp Crit Care Medicine. 2002;165:1062–67.
79. Anilkumar B. Jarali, G. Radhakrishnan. Stress, Obesity and Selected Health Problems among Professionals. Asian J. Nur. Edu. and Research. 2013; 3(3): 154-163.
80. S. Lavanya, Nalini Jeyavantha Santha, Gowri Sethu. A descriptive study to assess the level of stress among women with selected type of cancer in Erode Cancer Centre at Erode. Asian J. Nur. Edu. & Research. 2014; 4(3): 321-324.
81. Sampoornam. W. Stress and Quality of Life among Breast Cancer Patients. Asian J. Nur. Edu. & Research. 2014; 4(3): 325-327.
82. K. Priscilla, Nalini Jayavanth Santha, K. Priscilla. Massage Therapy- Complementary and Alternative Therapeutic approach. Asian J. Nur. Edu. and Research. 2014; 4(4): 516-519.
83. Devi. S, L N Samaga. Effect of transcendental meditation on stress and blood pressure among patients with systemic hypertension. Asian J. Nur. Edu. and Research. 2015; 5(1): 151-156.
84. Raghu Rama G N. A Study to assess the Effectiveness of Mindfulness Based Stress Reduction Meditation on Reducing Stress among Cancer Patients in Selected Hospitals at Mandya District. Asian J. Nur. Edu. and Research. 2016; 6(2): 188-190.
85. Christine Michael. Effect of Yoga Nidra on Stress among Nursing Students in Selected Colleges of Nursing. Asian J. Nur. Edu. and Research. 2017; 7(3): 429-440.
86. Helmi, Nanang Fakhrudin, Arief Nurrochmad, B. S. Arie Sudarmanto, Zullies Ikawati. In Vitro and In Silico Studies of Secang Wood (Caesalpinia sappan L.) Extracts and Brazilin as Natural Phosphodiesterase-1 (PDE1) Inhibitor for Herbal Cognitive Enhancer Development. Research J. Pharm. and Tech. 2020; 13(5): 2269-2274.
87. Bhavya Jose (Shimly. T. Thomas), Sr. Sajeena. Effectiveness of yoga therapy on stress and concentration among students of selected schools in Kerala. Asian J. Nur. Edu. and Research. 2017; 7(3): 299-304.
88. Jency Jose, Asha Liz Mani, Joseena. Relationship between coping Strategies and the Development of Post-Traumatic stress Disorder among Patients after an acute Myocardial Infarction. Asian J. Nursing Education and Research. 2021; 11(2):271-278.
89. Ch. Prudhvi Raju, G. Raveendra Babu, M. Sowjanya, M. Ramayyappa. Evaluation of Cancer Bio-markers through Hyphenated Analytical Techniques. Asian Journal of Pharmaceutical Analysis. 2021; 11(3):235-2.
90. Pradeep Sahu, Neha Pinkalwar, Ravindra Dhar Dubey, Shweta Paroha, Shilpi Chatterjee, Tanushree Chatterjee. Biomarkers: An Emerging Tool for Diagnosis of a Disease and Drug Development. Asian J. Res. Pharm. Sci. 2011; 1(1): 09-16.